PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4

Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells

(2016) Shinya Endo et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival

(2016) Hiroto Ohguchi et al.   Nature Communications

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

(2014) Y. X. Zhu et al.   BLOOD

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

(2014) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4

(2013) Kyoko Ochiai et al.   IMMUNITY

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

PU.1 Level-Directed Chromatin Structure Remodeling at the Irf8 Gene Drives Dendritic Cell Commitment

(2013) Jörg Schönheit et al.   Cell Reports

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

(2012) H. Yuki et al.   BLOOD

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

(2011) Antonia Lopez-Girona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Suppression of IRF4 by IRF1, 3, and 7 in Noxa Expression Is a Necessary Event for IFN- -Mediated Tumor Elimination

(2011) S. Piya et al.   MOLECULAR CANCER RESEARCH

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling

(2010) Jurate Savickiene et al.   DIFFERENTIATION

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: Role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation

(2009) Federica Brugnoli et al.   EXPERIMENTAL CELL RESEARCH

PU.1 Regulates Positive Regulatory Domain I-Binding Factor 1/Blimp-1 Transcription in Lymphoma Cells

(2009) S. Desai et al.   JOURNAL OF IMMUNOLOGY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL

(2009) S Ueno et al.   ONCOGENE

Thalidomide for treatment of multiple myeloma: 10 years later

(2008) A. Palumbo et al.   BLOOD

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Interferon regulatory factor family of transcription factors and regulation of oncogenesis

(2008) Akinori Takaoka et al.   CANCER SCIENCE

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

(2008) Enrique M Ocio et al.   LANCET ONCOLOGY

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE